BridgeBio Pharma Inc $ 66.17 -5.74 (-7.98%)
Volume:
827,375
Avg Vol (1m):
1,160,526
Market Cap $:
9.86 Bil
Enterprise Value $:
9.79 Bil
PE Ratio:
0.00
PB Ratio:
135.87
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.23 | ||
| Equity-to-Asset | 0.08 | ||
| Debt-to-Equity | 8.56 | ||
| Debt-to-EBITDA | -1.06 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 7.74 | ||
| Beneish M-Score | -5.75 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -5751.99 | ||
| Net Margin % | -5439.74 | ||
| ROE % | -175.75 | ||
| ROA % | -55.84 | ||
| ROC (Joel Greenblatt) % | -1971.01 | ||
| 3-Year EBITDA Growth Rate | -102.5 | ||
| 3-Year EPS without NRI Growth Rate | -86.4 |
BBIO
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 135.87 | ||
| PS Ratio | 945.29 | ||
| EV-to-EBIT | -20.89 | ||
| EV-to-EBITDA | -20.89 | ||
| EV-to-Revenue | 1187.23 | ||
| Current Ratio | 6.72 | ||
| Quick Ratio | 6.72 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 135.04 | ||
| Earnings Yield (Greenblatt) % | -4.78 |